A detailed history of Capital Cs Group, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Capital Cs Group, LLC holds 17,525 shares of TGTX stock, worth $602,860. This represents 0.28% of its overall portfolio holdings.

Number of Shares
17,525
Previous 17,525 -0.0%
Holding current value
$602,860
Previous $311,000 31.51%
% of portfolio
0.28%
Previous 0.17%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 25, 2022

SELL
$7.81 - $20.45 $36,707 - $96,115
-4,700 Reduced 21.15%
17,525 $167,000
Q4 2021

Jan 20, 2022

BUY
$15.2 - $35.51 $71,440 - $166,897
4,700 Added 26.82%
22,225 $423,000
Q3 2021

Oct 13, 2021

BUY
$21.78 - $40.45 $381,694 - $708,886
17,525 New
17,525 $591,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Capital Cs Group, LLC Portfolio

Follow Capital Cs Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Cs Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Cs Group, LLC with notifications on news.